We hope this becomes a valuable resource for you. Please tell us how to make it more useful, send corrections, and point out trials we have missed. (We know they’re out there.) We’ll add them as quickly as we can.
Table last updated 3/8/17
CAR-T and Other Cell Therapy Clinical Trials
| Agent | Sponsor (Partner) | Phase | Cancer Type | Latest Results | Main Findings| Trial ID |
or Name |
|---|---|---|---|---|---|---|
| axicabtagene ciloleucel (KTE-C19) | Kite Pharma | 2 | NHL | 17-Feb | 24/62 CR (3 mo) 36/101 CR (6 mo) DLBCL pts lower response rates than TL/PMBCL Safety (101 pts): 3 deaths, 13% CRS, 28% NE (≥gr3) | ZUMA-1 |
| axicabtagene ciloleucel (KTE-C19) | Kite Pharma | 1 | NHL | 15-Oct | 3/7 CR (12 mo) | ZUMA-1 |
| axicabtagene ciloleucel (KTE-C19) | National Cancer Institute | 1 | NHL | 16-Jun | 11/22 CR, 1 relapse | NCT00924326 |
| axicabtagene ciloleucel (KTE-C19) | Kite Pharma | 1/2 | adult ALL | 16-Dec | ZUMA-3/4 combined: 9/11 CR 5/13 gr3 or higher CRS 5/13 gr3 or higher neurotox | ZUMA-3 |
| axicabtagene ciloleucel (KTE-C19) | Kite Pharma | 1/2 | pediatric ALL | 16-Dec | ZUMA-3/4 combined: 9/11 CR 5/13 gr3 or higher CRS 5/13 gr3 or higher neurotox | ZUMA-4 |
| JCAR014* | Juno (Fred Hutchinson) | 1/2 | CLL, ALL, NHL | 16-Jun | 31/33 CR in ALL 19/41 CR in NHL 15/17 CR in CLL | NCT01865617 |
| JCAR015** | Juno (Memorial Sloan Kettering) | 1 | adult ALL | 16-Jun | 41/51 initial CR 73% OS (6 mo) | NCT01044069 |
| JCAR015** | Juno (Memorial Sloan Kettering) | 1 | NHL | 15-Jun | 5/8 initial CR | NCT01840566 |
| JCAR015** | Juno | 2 | adult ALL | 17-Mar | Trial and all JCAR015 development ended after 5 deaths. | ROCKET |
| JTCR016 | Juno (Fred Hutchinson) | 1/2 | AML | 16-Dec | Post-BMT treatment 12/12 CR median follow-up 2+ yrs | NCT01640301 |
| JTCR016 | Juno (Fred Hutchinson) | 1 | NSCLC, mesothelioma | 16-Apr | 3 treated, 1 PR, 1 "stable" | NCT02408016 |
| JCAR017 | Juno | 1 | NHL | 16-Dec | 12/20 CR gr3-4 neurotox in 3/22 pts no "severe" CRS | TRANSCEND |
| JCAR017 | Juno (Seattle Childrenâs) | 1/2 | pediatric ALL | 16-Nov | 40/43 initial CR (21 days) 51% EFS and 69.5% OS (12 mo) 53% DFS and 74% OS (12 mo) | NCT02028455 |
| JCAR018 | Juno (National Cancer Institute) | 1 | pediatric ALL | 16_Apr | Medium dose: 3/3 CR (3-6 mo) Low dose: 1/6 CR w/relapse (3 mo) | NCT02315612 |
| CTL019 | Novartis (U. Penn) | 1 | pediatric ALL | 15-Dec | 55/59 CR (1 mo) 18/38 CR (12 mo) | NCT01626495 |
| CTL019 | Novartis (U. Penn) | 2 | NHL | 15-Dec | 7/26 CR (3 mo) 13/26 CR (6 mo) | NCT02030834 |
| CTL019 | U. Penn | N/A | adult ALL | 15-Dec | 15/27 CR (better rate in group receiving higher dose over 3 days) | NCT01029366 |
| CTL019 | Novartis (U. Penn) | 1 | multiple myeloma | 15-Sep | 1/10 CR (12 mo) 6/10 PFS (1-8 mo) | NCT02135406 |
| CTL019 | Novartis (U. Penn) | 2 | pediatric ALL | 16-Dec | 41/50 CR (3 mo) 25/50 relapse free (6 mo) 48% serious CRS; no deaths | ELIANA |
| CTL019 | Novartis | 2 | adult DLBCL | N/A | Due 16-Dec | JULIET |
| CART-BCMA | U. Penn (rights to Novartis) | 1 | multiple myeloma | 16-Nov | 6 pts, 1 "stringent" CR, 1 PR, high toxicity | NCT02546167 |
| bb2121 | Bluebird (Celgene) | 1 | multiple myeloma | 16-Nov | 7 of 9 pts with response 2 "stringent" CR, 1 VGPR, 4 PR | NCT02658929 |
| BCMA CAR | National Cancer Institute | 1 | multiple myeloma | 16-Sep | 12 pts, 2 VGPR, 1 stringent CR then relapse (17 wks) | NCT02215967 |
| UCART-19 | Cellectis | N/A | ALL | 16-Dec (See p. 53) | two infants in CR, 1 adult deceased | compassionate use |
| UCART-19 | Servier (Cellectis) | 1 | pediatric ALL | 16-Dec (See p. 53) | 2 pts: 1 CR (4 mo), 1 relapsed (6 mo) w/gr3 CRS | PALL |
| UCART-19 | Servier (Cellectis) | 1 | adult ALL | 16-Dec (See p. 53) | 2 pts: 1 CR (4 mo), 1 deceased | CALM |
| NY-ESO TCR | Adaptimmune | 1/2 | synovial sarcoma | 16-Oct | 7/20 OR across 4 cohorts 6/12 OR in cohort 1, median duration 31 wks | NCT01343043 |
| NY-ESO TCR | Adaptimmune | 1/2 | multiple myeloma | 16-Jun | 3/22 CR (100 days) 20/22 OR (100 days) | NCT01352286 |
| NY-ESO TCR | Adaptimmune | 1/2 | melanoma | 16-Jun | 0/4 OR | NCT01350401 |
| NY-ESO TCR | Adaptimmune | 1/2 | ovarian cancer | 16-Jun | 0/6 OR | NCT01567891 |
| BPX-501 | Bellicum Pharma | 1/2 | BMT support for cancer, other blood diseases | 16-Dec | 16/17 leukemia pts & 35/35 non-cancer pts "disease-free." Median follow-up 7 mo (cancer), 25-34 mo (non-cancer) | BP-004 |
| NKG2D CAR T | Celyad | 1 | AML, myeloma | 16-Nov | 11 pts, 0-11 ORs after 28 days; 9 went to "subsequent therapies" | NCT02203825 |
| HER2-CAR | Baylor College of Medicine | 1 | Her2+ glioblastoma | 15-Nov | 8/16 ORR: 7 pts stable disease > 6 wks. Median OS 11.6 months from infusion. | NCT01109095 |
| HER2-CAR | Baylor College of Medicine | 1/2 | Her2+ sarcoma | 15-May | 19 pts. Median OS 10.3 mos. (Range 5.1 to 29.1 mos.) | NCT00902044 |
| CAR-K+ | Baylor College of Medicine | 1 | Lymphoma, myeloma, leukemia | 16-Jun | 9 NHL/CLL pts: 2 CR, 1 PR. 7 myeloma pts: 4 w/stable disease. | NCT00881920 |
| TIL + IL-2 | Lion Bio (NCI) | 1 | melanoma | 16-July | 101 pts: 24% CR in both arms. Radiation: median OS 38.2 mo No radiation: 36.6 mo | NCT01319565 |
*JCAR014 is a non-commercial program that Juno has said is only intended for early clinical studies.
**Juno ended all JCAR015 development in March 2017.
Clinical terms
DFS: Disease-free survival. Length of time post-treatment the patient survives without sign of cancer.
PFS: Progression-free survival. Length of time post-treatment the patient survives without the cancer getting worse.
CR: Complete response, or complete remission: A patient’s cancer is undetectable.
OR: Objective response. A patient’s treatment has made a measurable effect on the cancer.
PR: Partial response. (VGPR = very good partial response.)
OS: Rate or percentage of people who survive after the start of treatment.
CRS: Cytokine release syndrome. A dangerous immune side effect triggered by T cell activity against cancer cells.
Disease and other abbreviations
ALL: Acute lymphocytic (or lymphoblastic) leukemia
AML: Acute myeloid leukemia
BMT: Bone marrow transplant
CLL: Chronic lymphocytic leukemia
NHL: Non-Hodgkin lymphoma. Subtypes include DLBCL (diffuse large B-cell lymphoma), PMBCL (primary mediastinal large B-cell lymphoma), and TFL (transformed follicular lymphoma).
NSCLC: Non small cell lung cancer
Photo of William Coley courtesy of The Wellcome Trust via Creative Commons.
